Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Catalyst-rich dermatology name: strong recent ZORYVE revenue, raised 2026 sales guidance, and guidance for continued positive operating cash flow are coupled with a pediatric sNDA filing expected in Q2 2026 and early ARQ-234 Phase 1 progress; despite current technical weakness, any sNDA/regulatory or cash-flow update in the next few days could trigger a sharp rebound from oversold levels.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Early Rebound ⢠Resistance Test ⢠Higher Low Support Level: $27.0 to $26.7 Resistance Level: $28.5 to $28.8 Over the last month, ARQT has maintained a modest uptrend with a sharp early-July rebound, but momentum has cooled and price remains capped below $28.8 resistance.
Sentiment & News
Key News Insights: ⢠Pediatric approvals ⢠Infant filing ⢠Commercial expansion Arcutis delivered multiple ZORYVE regulatory wins and commercialization moves, reinforcing its growth outlook and adding a near-term catalyst ahead of Q2 results.
AI Summary
ARQT should now be viewed primarily as a commercial dermatology execution story rather than a binary biotech bet, because ZORYVE's FDA-driven label expansion is translating into strong revenue growth and positive operating cash flow, but the stock still hinges on sustaining adoption, reimbursement, and margin leverage given heavy ZORYVE concentration and ongoing valuation risk.
Description
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company developing topical treatments for dermatological conditions. Its lead asset is a roflumilast cream that has completed Phase III trials for plaque psoriasis and atopic dermatitis, and its pipeline includes additional roflumilast and topical JAK1 inhibitor formulations targeting scalp and skin disorders such as seborrheic dermatitis, hand eczema, vitiligo and alopecia areata. The company was incorporated in 2016, changed its name in October 2019, and is headquartered in Westlake Village, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 4 | Mar 11 | ARQT | Arcutis Biotherapeutics, Inc. | Catalyst-rich dermatology name: strong recent ZORYVE revenue, raised 2026 sales guidance, and guidance for continued positive operating cash flow are coupled with a pediatric sNDA filing expected in Q2 2026 and early ARQ-234 Phase 1 progress; despite current technical weakness, any sNDA/regulatory or cash-flow update in the next few days could trigger a sharp rebound from oversold levels. | Closed | -0.7% |
| Dec 2 | Dec 9 | ARQT | Arcutis Biotherapeutics, Inc. | Compelling short-term growth supported by strong Q3 revenue growth (+122% YoY), recent FDA pediatric approvals, upcoming Phase 2 topline data in Q1 2026, solid profitability trends, strong liquidity with $191M cash, and a 20% price surge with bullish technical momentum. | Closed | +1.1% |